Instituto de Medicina Veterinária, Universidade Federal do Pará, Castanhal, Pará CEP 68740-970, Brazil.
Centro de Desenvolvimento Tecnológico, Núcleo de Biotecnologia, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul CEP 96160-000, Brazil.
Toxins (Basel). 2021 Aug 26;13(9):594. doi: 10.3390/toxins13090594.
The alpha (CPA), beta (CPB) and epsilon (ETX) toxins of are responsible for causing diseases that are difficult to eradicate and have lethal potential in production animals. Vaccination of herds is still the best control strategy. Recombinant clostridial vaccines have shown good success at inducing neutralizing antibody titers and appear to be a viable alternative to the conventional production of commercial clostridial toxoids. Research is still needed on the longevity of the humoral immune response induced by recombinant proteins in immunized animals, preferably in target species. The objective of this study was to measure the humoral immune response of cattle immunized with trivalent vaccines containing the recombinant proteins alpha (rCPA), beta (rCPB) and epsilon (rETX) of produced in at three different concentrations (100, 200, and 400 µg) of each protein for 12 months. The recombinant vaccines containing 200 (RV2) and 400 µg (RV3) yielded statistically similar results at 56 days. They performed better throughout the study period because they induced higher neutralizing antibody titers and were detectable for up to 150 and 180 days, respectively. Regarding industrial-scale production, RV2 would be the most economical and viable formulation as it achieved results similar to RV3 at half the concentration of recombinant proteins in its formulation. However, none of the vaccines tested induced the production of detectable antibody titers on day 365 of the experiment, the time of revaccination typically recommended in vaccination protocols. Thus, reiterating the need for research in the field of vaccinology to achieve greater longevity of the humoral immune response against these clostridial toxins in animals, in addition to the need to discuss the vaccine schedules and protocols adopted in cattle production.
是引起难以根除的疾病的罪魁祸首，并且对生产动物具有致命潜力。对畜群进行疫苗接种仍然是最好的控制策略。重组梭菌疫苗已被证明在诱导中和抗体滴度方面非常成功，并且似乎是替代传统生产商业梭菌类毒素的可行方法。仍然需要研究重组蛋白在免疫动物中诱导的体液免疫反应的持久性，最好在目标物种中进行研究。本研究的目的是测量用含有在生产的三种重组蛋白（rCPA、rCPB 和 rETX）的三价疫苗免疫的牛的体液免疫反应，三种疫苗中每种蛋白的浓度分别为 100、200 和 400 µg，持续 12 个月。含有 200（RV2）和 400 µg（RV3）重组蛋白的重组疫苗在 56 天时产生了统计学上相似的结果。它们在整个研究期间表现更好，因为它们诱导了更高的中和抗体滴度，并且分别可检测长达 150 和 180 天。关于工业规模生产，RV2 将是最经济和可行的配方，因为它以其配方中重组蛋白浓度的一半达到了与 RV3 相似的结果。然而，在实验的第 365 天，即疫苗接种方案中通常建议的再接种时间，没有一种疫苗能诱导可检测抗体滴度的产生。因此，除了需要讨论在牛生产中采用的疫苗接种计划和方案外，还需要在该领域进行疫苗学研究，以实现针对这些梭菌毒素的体液免疫反应的更长持久性。
